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The present study investigated the potential of biochanin A, a phytoestrogenic isoﬂavone of red clover (Triﬂolium pratense), for
use in treating asthma or chronic obstructive pulmonary disease (COPD). Biochanin A (100μmol/kg, orally (p.o.)) signiﬁcantly
attenuated airway resistance (RL), enhanced pause (Penh), and increased lung dynamic compliance (Cdyn) values induced by
methacholine (MCh) in sensitized and challenged mice. It also signiﬁcantly suppressed an increase in the number of total
inﬂammatory cells, neutrophils, and eosinophils, and levels of cytokines, including interleukin (IL)-2, IL-4, IL-5, and tumor
necrosis factor (TNF)-α in bronchoalveolar lavage ﬂuid (BALF) of the mice. However, it did not inﬂuence interferon (IFN)-γ
levels. Biochanin A (100μmol/kg, p.o.) also signiﬁcantly suppressed the total and ovalbumin (OVA)-speciﬁc immunoglobulin E
(IgE) levels in the serum and BALF, and enhanced the total IgG2a level in the serum of these mice. The PDE4H/PDE4L value of
biochaninAwascalculatedas>35.BiochaninAdidnotinﬂuencexylazine/ketamine-inducedanesthesia.BiochaninA(10∼30μM)
signiﬁcantly reduced cumulative OVA (10∼100μg/mL)-induced contractions in the isolated guinea pig trachealis, suggesting that
it inhibits degranulation of mast cells. In conclusion, red clover containing biochanin A has the potential for treating allergic
asthma and COPD.
1.Introduction
Red clover (Triﬂolium pratense L., Fabaceae) contains
formononetin (4
 -O-methyldaidzein), biochanin A (4
 -O-
methylgenistein), daidzein, and genistein in relative pro-
portions of 5.46%, 1.97%, 0.43%, and 0.11% [1]. These
phytoestrogenic isoﬂavones are also present in soy; however,
the contents of formononetin and biochanin A are substan-
tially higher in red clover [2]. Since the 19th century, red
clover tea or tincture has been used in North America as
an antispasmodic for whooping cough, measles, bronchitis,
laryngitis, and tuberculosis [3]. Accordingto an early edition
of the National Formulary, red clover has also been used as
a treatment for asthma. However, the eﬃcacy of most of the
above-mentioned traditional red clover treatments has not
been tested in randomized, placebo-controlled clinical stud-
ies [2]. Recently, botanical dietary supplements containing
red clover have received a great deal of attention for treating
thesymptomsofmenopause,themaintenance/improvement
of bone, and cardiovascular health. It has also been reported
to have a benign eﬀect on breasts and the endometrium
[2].Inaddition,estrogenreceptor-targetedtherapeuticshave
proven successful in treating breast cancer and metabolic
disorders,sincephytoestrogenswere reportedasanestrogen-
related receptor α agonist [4]. The cancer-protective eﬀects
of ﬂavonoids are attributed to a wide variety of mechanisms,
including modulating enzyme activity resulting in a decrease
in the carcinogenicity of xenobiotics. A number of naturally2 Evidence-Based Complementary and Alternative Medicine
occurring ﬂavonoids have been shown to modulate the
cytochrome P450 (CYP) enzyme system, including the
induction of speciﬁc CYP isozymes, and the activation or
inhibition of these enzymes. Isoﬂavones inhibit the activity
of aromatase (CYP19), thus decreasing estrogen biosynthesis
and producing antiestrogenic eﬀects, important in the treat-
ment of breast and prostate cancer [5]. In 2004, we reported
that biochanin A selectively inhibited phosphodiesterase
(PDE)4 activity with an IC50 value of 8.5μM, although
PDE1 (IC50, 29.1μM) and PDE2 (IC50, 27.9μM) activities
were also inhibited by the compound. However, biochanin
A did not inhibit (IC50 > 100μM) PDE3 or PDE5 activities
[6]. Whether formononetin inhibits PDE4 activity remains
unknown. In our previous report, genistein and daidzein
selectively inhibited PDE2 and PDE3 activities, respectively
[6].
PDEs are classiﬁed according to primary protein and
complementary (c)DNA sequences, cofactors, substrate
speciﬁcities, and pharmacological roles. It is now known
that PDEs comprise at least 11 distinct enzyme families
hydrolyzing cAMP and/or cGMP [7]. PDE1∼5 isozymes,
which are calcium/calmodulin-dependent (PDE1), cGMP-
stimulated (PDE2), cGMP-inhibited (PDE3), cAMP-speciﬁc
(PDE4),andcGMP-speciﬁc(PDE5)werefoundtobepresent
in the canine trachea [8], guinea pig lung [9], and human
bronchi [10]. PDE3 and PDE4 were identiﬁed in the guinea
pig airway [11], but other isozymes might also be present.
Rolipram, a prototype PDE4 selective inhibitor, has both
ah i g h( P D E 4 H)a n dl o w( P D E 4 L)a ﬃnity for PDE4. In
general, it is believed that the inhibition of PDE4H is
associated with adverse responses, such as nausea, vomiting,
and gastric hypersecretion, and that the inhibition of PDE4L
is associated with anti-inﬂammatory and bronchodilating
eﬀects. Therefore the therapeutic ratio of selective PDE4
inhibitors for use in treating asthma and chronic obstructive
pulmonary disease (COPD) is deﬁned as the PDE4H/PDE4L
ratio [12]. In this study, biochanin A showed a higher
PDE4H/PDE4L ratio (>35) than the selective PDE4 inhibitor
AWD 12-281 (11) [13]. The aim of the present study was
to determine the potential of biochanin A, contained in red
clover, in treating asthma or COPD.
2.Methods
2.1. Reagents and Animals. Biochanin A (mol wt., 284.27),
ovalbumin(OVA),methacholine (MCh),polyethyleneimine,
aluminum sulfate hexadecahydrate, dimethylsulfoxide
(DMSO),bis(2-hydroxyethyl)aminotris(hydroxymethyl)meth-
ane (Bis-Tris), chloralose, urethane, Tris-HCl, benzamidine,
phenylmethanesulfonyl ﬂuoride (PMSF), Tween 20, d,l-
dithiothreitol, ethylenediaminetetraacetic acid (EDTA),
xylazine, and ketamine were purchased from Sigma
Chemical (St. Louis, MO, USA). Rolipram and 4-(3-butoxy-
4-methoxybenzyl)-2-imidazolidinone (Ro 20-1724) were
purchased from Biomol (Plymouth Meeting, PA, USA).
Freund’s complete adjuvant (Mycobacterium butyricum)w a s
purchased from Pierce Biotechnology (Rockford, IL, USA).
Mouse T helper (Th)1/Th2 cytokine CBA kits, and mouse
IgE and IgG2a ELISA sets were purchased from Pharmingen
(San Diego, CA, USA). Polyethyleneglycol (PEG) 400, and
ethyl alcohol were purchased from Merck (Darmstadt,
Germany). [Methyl-3H]-Rolipram was purchased from
Amersham Pharmacia Biotech (Buckinghamshire, UK).
Other reagents, such as CaCl2,M g C l 2,a n dN a C l ,w e r eo f
analytical grade. Biochanin A, rolipram, and Ro 20-1724
were dissolved in a mixture of ethyl alcohol and DMSO
(1:1).Otherdrugswere dissolvedindistilled water.The ﬁnal
concentration of ethyl alcohol or DMSO in vitro was ≤0.5%,
and did not signiﬁcantly inﬂuence tracheal contractions or
the binding of test drugs to high-aﬃnity rolipram binding
sites (HARBSs).
Male Hartley guinea pigs (500∼600g) and female
BABL/c mice at age 8–12 weeks were obtained from the
Animal Center of the National Science Council (Taipei,
Taiwan). The animals were housed in ordinary cages at 22 ±
1◦C with a humidity of 50%∼60% under a constant 12/12-h
light/darkcycleandprovidedwithfoodandwateradlibitum.
Under a protocol approved by the Animal Care and Use
CommitteeofTaipeiMedicalUniversity,thefollowinginvivo
and in vitro experiments were performed.
2.2. Determination of PDE4H Values. After the above-
described guinea pigs were sacriﬁced, the whole brains were
removed and homogenized with a glass/Teﬂon homogenizer
(Glas-Col, Terre Haute, IN, USA) in 10 volumes of cold
medium (pH 6.5) containing 20mM Bis-Tris, 2mM ben-
zamidine, 2mM EDTA, 50mM sodium chloride, 0.1mM
PMSF, and 1mM dithiothreitol. At 4◦C, the homogenate
was centrifuged at 170g for 5min to remove connective
tissues and blood vessels. The suspended homogenate was
then recentrifuged at 40,000g for 30min to separate the
cytosolic and particulate portions. After washing three
times with homogenizing buﬀer, the particulate portion
was resuspended at a concentration of 400mg/mL (wet
weight/volume). The particulate portion mainly consisted of
cell membranes. The ability of biochanin A (10∼300μM)
or rolipram (0.1∼1000nM), a reference drug, to bind to
HARBSs of the membranes was determined by replacing
2nM [ 3H]-rolipram in a reaction buﬀer at 30◦Cf o r1 h ,
according to a modiﬁed version of method described by
previous investigators [14, 15]. Brieﬂy, the reaction buﬀer
consistedof50mMTris-HCland5mMMgCl2 (pH7.5).The
total volume of the reaction mixture was 25μL, consisting
of 10μL of particulate suspension, 10μLo f[ 3H]-rolipram,
and 5μL of biochanin A or rolipram. After 1h, the reaction
was terminated by placing the reaction vessel in crushed ice.
The reaction mixture was then transferred onto Whatman
GF/B glass-ﬁber ﬁlters soaked in a 0.3% polyethyleneimine
solution in a minifunnel. The reaction mixture was ﬁltered
by centrifuging it at 90g for 10sand the ﬁltrate was collected
in a 1.5-mL Eppendorf tube with a top adapted to ﬁt the
outlet of the minifunnel. The ﬁlters were each washed three
times with 300μLo fr e a c t i o nb u ﬀer in the same manner and
transferred into a 2mL cocktail for radiation counting (total
binding) using a β-scintillation counter (Beckman, Fuller-
ton, CA, USA). Nonspeciﬁc binding, which was deﬁned in
the presence of 10μM Ro 20-1724, was subtracted from
the total binding to yield the speciﬁc binding. The eﬀectiveEvidence-Based Complementary and Alternative Medicine 3
concentrations (EC50) values of biochanin A and rolipram,
at which half of the [3H]-rolipram bound with HARBSs of
cell membranes was displaced, were deﬁned as the PDE4H
values and these may be correlated with adverse eﬀects, such
as nausea, vomiting, and gastric hypersecretion [16].
2.3. Airway Hyperresponsiveness In Vivo. Ten female BABL/c
mice in each group were sensitized on days 0 and 14 by an
intraperitoneal (i.p.) injection of 20μgo fO V Ae m u l s i ﬁ e di n
2.25mg aluminum hydroxide gel, prepared from aluminum
sulfate hexadecahydrate, in a total volume of 100μL. On day
21,these mice were injected with (i.p.) 100μLo fam i x t u r eo f
1% OVA and Freund’s complete adjuvant (1:1). Mice were
challengedviatheairway ondays28,29,and30byultrasonic
nebulization using 1% OVA in saline for 30min. After the
lastoftheprimaryOVAchallenges[17],airwayhyperrespon-
siveness (AHR) was assessed on day 32 (48h after 1% OVA
provocation) in each group. Each group of mice was orally
(p.o.)administered a vehicle (control) or30∼100μmol/kg of
biochaninA2hbeforeand6and24hafterOVAprovocation.
For comparison, sham-treated mice were sensitized but
challenged with saline instead of 1% OVA (nonchallenged).
The vehicle, a mixture of alcohol:DMSO:Tween 20:saline
(0.5:0.5:1:8, v/v) or biochanin A was orally administered
at a volume of 0.01mL/g of body weight. AHR was assessed
using two methods: (1) in anesthetized ventilated mice,
AHR was assessed as previously described in [18]b y
measuring changes in airway resistance (RL,c m H 2O/mL/s)
and lung dynamic compliance (Cdyn,m L / c m H 2O) after
a challenge with aerosolized methacholine (MCh, 0.78∼
25mg/mL) using FlexiVent system (SCIREQ, Montreal,
Quebec, Canada). Anesthetized (urethane 600mg/kg and
chloralose 120mg/kg, i.p.) and tracheostomized (stainless
steel cannula, 18 G) mice were mechanically ventilated
(150breaths/min, tidal volume of 10mL/kg, positive end-
expiratory pressure of 3cmH2O); (2) in unrestrained ani-
mals,AHRwasassessed bybarometric plethysmography[19]
using a whole-body plethysmograph (WBP) and analyzed
using Life Science Suite P3 Analysis Modules (Gould,
LDS Test and Measurement LLC, Valley View, OH, USA)
s o f t w a r e .M i c ew e r ep l a c e di n t ot h em a i nc h a m b e ro ft h e
WBP and the baseline enhanced pause (Penh)v a l u ew a s
determined. The mice were then nebulized with phosphate-
buﬀered saline (PBS) and subsequently with increasing
doses (6.25∼50mg/mL) of methacholine (MCh) for 3min
per nebulization and readings were made of the breathing
parameters 3min after each nebulization to determine Penh
values.Twenty-four hoursafterthePenh determination,these
mice were anesthetized with pentobarbital (50mg/kg, i.p.),
and lavaged viaat r a c h e a lt u b ew i t hP B S( 1×1.0mL,37 ◦C).
After lavage, blood was collected from the jugular vein and
allowed to coagulate. The collected bronchoalveolar lavage
ﬂuid (BALF) and coagulated blood were centrifuged at 630g
for 7min and at 3700g for 10min, respectively, at 4◦C.
After centrifugation, the supernatants of BALF and serum
were stored at −20◦C until the determination of cytokines,
including interleukin (IL)-2, IL-4, IL-5, tumor necrosis
factor (TNF)-α, and interferon (IFN)-γ by ﬂow cytometric
methods [20] using mouse Th1/Th2 cytokine CBA kits, and
total immunoglobulin E (IgE) and total IgG2a using enzyme-
linked immunosorbent assay (ELISA) kits (Pharmingen, San
Diego, CA, USA) according to the recommendations of the
manufacturer. The minimum concentrations of cytokine
and Ig were 1pg/mL and 1ng/mL, respectively. All the
undetectable data were taken as 0.5pg/mL and 0.5ng/mL,
respectively. OVA-speciﬁc IgE was measured by a slightly
modiﬁed version of the method described previously [21].
Wells were coated with 100μLo fO V A( 2 0 μg/mL) instead
of the capture antibody. Levels were expressed in arbitrary
units, where 1 arbitrary unit equaled the optical density of
t h es a m p l ed i v i d e db yt h eo p t i c a ld e n s i t yo fu n c h a l l e n g e d
mouse serum or BALF (standard). The pellet from BALF
was resuspended in ACK lysing buﬀer (1.658g NH4Cl, 0.2g
KHCO3 and 1.44mg EDTA in 200mL of water) to lyse
the residual erythrocytes in each sample. The number of
inﬂammatory cells was counted using a hemocytometer
(Hausser Scientiﬁc, Horsham, PA, USA). Cytospun slides
were stained and diﬀerentiated in a blinded fashion by
counting at least 100 cells under light microscopy.
2.4. Xylazine/Ketamine-Induced Anesthesia. According to the
modiﬁed version of the method described by Robichaud
et al. [22], biochanin A (30∼300μmol/kg, subcutaneously
(s.c.)) or Ro 20-1724 (0.01∼1μmol/kg, s.c.), a reference
drug, was injected into 8∼12 week-old female BALB/c
mice 1h or 15min prior to an i.p. injection of xylazine
(10mg/kg)/ketamine (70mg/kg). The vehicle (control) for
biochanin A or for Ro 20-1724 was a mixture of alco-
hol:DMSO:Tween 20:saline (0.5:0.5:1:8, v/v), or alco-
hol:DMSO:PEG 400:saline (0.5:0.5:1:8, v/v), respec-
tively. The duration of anesthesia was measured from the
time of losing the righting reﬂex (i.e., when a mouse remains
on its back no longer spontaneously righting itself to a prone
position), until its return [22].
2.5. OVA-Induced Tracheal Contractions In Vitro. Male Hart-
leyguinea pigs (500∼600g)were sensitized by intramuscular
injections into each thigh of 0.7mL of 5% (w/v) OVA
in saline on days 1, 4, and 43, and in adjuvant on days
25 and 39, according to a modiﬁed version of previously
described method [23]. Three days after the last injection,
sensitized guinea pigs were sacriﬁced by cervical dislocation,
and the tracheas were removed. Each trachea was cut into
six segments. Each segment consisted of three cartilage rings.
All segments were cut open opposite the trachealis. After the
segments were randomized to minimize regional variability,
one end was tied to holders via silk sutures, placed in
5mL of normal Krebs solution containing indomethacin
(3μM), gassed with a mixture of 95% O2 plus 5% CO2
at 37◦C, and the other end of each segment was attached
to force displacement transducers (Grass FT03, Quincy,
MA, USA) for the isometric recording of tension changes
on a polygraph (Gould RS3200, Cleveland, OH, USA).
The composition of the normal Krebs solution was (mM):
NaCl 118, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2 2.5,
NaHCO3 25, and dextrose 10.1. Tissues were suspended
in normal Krebs solution under an initial tension of 1.5g
and allowed to equilibrate for at least 1h and washed at4 Evidence-Based Complementary and Alternative Medicine
15-min intervals. After the tissues were precontracted with
KCl (60mM) and washed with normal Krebs solution, OVA
(0.1∼100μg/mL) was cumulatively added, and contractions
were allowed to reach a steady state at each concentration.
To evaluate the suppressive eﬀect of biochanin A on OVA-
induced contractions, each tissue sample was preincubated
with concentration (3∼30μM) of biochanin A or its vehicle
for 15 min and then again challenged with cumulative OVA.
Therefore, log concentration-response curves of OVA were
constructed in the absence and presence of biochanin A.
The tension of the precontraction induced by KCl was set at
100%.
2.6. Statistical Analysis. Concentrations of test compounds
producing50%ofthemaximumactivity(IC50 orEC50 value)
were compared. The IC50 and EC50 values were calculated
employing nonlinear regression analysis using SigmaPlot
10.0 (Sigma Chemical). All values are given as the mean ±
SEM. Diﬀerences among values were statistically calculated
using one-way analysis of variance (ANOVA), and deter-
mined by Dunnett’s test. The diﬀerence between two values,
however, was determined by Student’s t-test. Diﬀerences of
P<. 05 were considered statistically signiﬁcant.
3.Results
3.1. PDE4H/PDE4L Ratios. Biochanin A (10∼300μM) con-
centration-dependently displaced [3H]-rolipram binding on
HARBSsofguineapigbraincellmembranes(Figure 1(a)).At
the highest concentration (300μM ) ,h o w e v e r ,t h ep e r c e n t a g e
displacement by biochanin A was 23.4% ± 2.9% (n =
4). The concentration cannot exceed 300μMo w i n gt o
the solubility of biochanin A. In other words, the EC50
value of biochanin A for the displacement was >300μM.
Rolipram (0.1∼1000nM), a selective PDE4 inhibitor, also
concentration-dependentlydisplaced[3H]-roliprambinding
on HARBSs (Figure 1(b)). In contrast to biochanin A, the
percentage of the displacement by rolipram at the highest
concentration (1000nM) was 102% ± 1.5% (n = 8). The
EC50 value of rolipram for displacement was 5.2 ± 1.9nM
(n = 8). As deﬁned in the Methods section, therefore, the
PDE4H values of biochanin A and rolipram were >300μM
and 5.2 ± 1.9nM, respectively. To inhibit PDE4 catalytic
activity, the IC50 values of biochanin A and rolipram were
reportedly required to be 8.5μM[6]an d2.3μM[24],respec-
tively. These were adopted as the PDE4L values, because the
anti-inﬂammatory eﬀectsof PDE4inhibitors were reportedly
associated with the inhibition of PDE4 catalyticactivity [25],
and the anti-inﬂammatory eﬀects were correlated with the
inhibition of PDE4L [16]. Thus, PDE4H/PDE4L values of
biochanin A and rolipram were calculated to be >35 and
0.002, respectively.
3.2. Suppression of Airway Hyperresponsiveness In Vivo.
RL values at the baseline for the control (vehicle), non-
challenged, and 30, and 100μmol/kg biochanin A groups
were 0.94 ± 0.14, 1.07 ± 0.03, 1.09 ± 0.05, and 1.26 ±
0.06cmH2O/ml/s, respectively, and these values did not
diﬀer signiﬁcantly. RL values of PBS nebulization for each
group were 0.98 ± 0.16, 1.07 ± 0.03, 1.14 ± 0.07, and
1.26 ± 0.05cmH2O/ml/s, respectively, and again did not
diﬀer signiﬁcantly. Administration of nebulized PBS did not
inﬂuencetheRL valuesofthebaselineinanygroup.However,
MCh (6.25∼25mg/mL) concentration-dependently and sig-
niﬁcantly increased RL values (Figure 2(a))a n dd e c r e a s e d
Cdyn values (Figure 2(b)) in the control sensitized and chal-
lenged group when compared to the nonchallenged group.
Biochanin A 100μmol/kg (p.o.) signiﬁcantly suppressed
these changes (Figure 2).
Penh values at the baseline for the control (vehicle),
nonchallenged, and 30,and100μmol/kgbiochaninAgroups
were 2.45 ± 0.05, 2.45 ± 0.03, 2.44 ± 0.10, and 2.50 ± 0.04,
respectively, and these values did not diﬀer signiﬁcantly.
Penh values of PBS nebulization for each group were 2.40 ±
0.05, 2.46 ± 0.06, 2.40 ± 0.08, and 2.43 ± 0.08, respectively,
and again did not diﬀer signiﬁcantly. Administration of
nebulized PBS did not inﬂuence the Penh value of the
baseline in any group. However, MCh (6.25∼50mg/mL)
concentration-dependentlyincreased Penh valuesfrom1-fold
of PBS exposure to 2.00 ± 0.06-fold in control sensitized
and challenged mice (Figure 3(a)). Penh values of MCh at
25 and 50mg/mL in control sensitized and challenged mice
were signiﬁcantly enhanced compared to those in nonchal-
lenged mice. Biochanin A (100μmol/kg, p.o.) signiﬁcantly
attenuatedtheenhancementofPenh valuesinducedby25and
50mg/mL MCh (Figure 3(a)).
3.3. Suppression of Inﬂammatory Cells in BALF. Total
inﬂammatory cells, macrophages, lymphocytes, neutrophils,
and eosinophils from the BALF of control-sensitized and
challenged mice increased signiﬁcantly when compared to
those of nonchallenged mice (Figure 3(b)). Biochanin A
(100μmol/kg, p.o.) also signiﬁcantly suppressed the increase
in the number of total inﬂammatory cells, neutrophils, and
eosinophils (Figure 3(b)).
3.4. Suppression of Cytokines in BALF. Compared to those in
nonchallenged mice, levels of cytokines, such as IL-2, IL-4,
IL-5, IFN-γ,a n dT N F - α, in the BALF of control-sensitized
and challenged mice signiﬁcantly increased (Figure 3(c)).
Biochanin A (100μmol/kg, p.o.) signiﬁcantly suppressed
increases in the levels of IL-2, IL-4, IL-5, and TNF-α.E v e n
at a dose of 30μmol/kg, biochanin A signiﬁcantly suppressed
increases in the levels of IL-4 and IL-5. However, biochanin
A at a dose of 30 or 100μmol/kg did not inﬂuence the level
of IFN-γ compared to the control (Figure 3(c)).
3.5. Eﬀects on IgG2a and IgE in the Serum and BALF. The
total IgG2a level in the serum of control sensitized and
challenged mice was signiﬁcantly reduced compared to that
of nonchallenged mice. Biochanin A (100μmol/kg, p.o.)
signiﬁcantly reversed this reduction (Figure 4(a)). Levels of
totalandOVA-speciﬁcIgEintheserumandBALFforcontrol
sensitized and challenged mice were signiﬁcantly enhanced
compared to those of nonchallenged mice. Biochanin A
(100μmol/kg, p.o.) signiﬁcantly suppressed these enhance-
ments (Figures 4(b)–4(e)).Evidence-Based Complementary and Alternative Medicine 5
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Figure 1: Displacement of [3H]-rolipram by biochanin A (a) and rolipram (b) in high-aﬃnity rolipram binding sites of guinea pig whole-
brain particulates. Each value represents the mean ± SEM. The numbers of experiments for biochanin A and rolipram were 4 and 8,
respectively.
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Figure 2:Eﬀects ofbiochaninA(30∼100μmol/kg,p.o.) onRL (a) andCdyn (b) in sensitizedmice receiving aerosolized methacholine (MCh,
0.78∼25mg/mL) 2 days after primary allergen challenge. ##P<. 01, and ###P<. 001, compared to the nonchallenged group. ∗∗∗P<. 001,
compared to the control (vehicle) group. The number of mice in each group was 10. PBS: phosphate-buﬀered saline.
3.6. No Eﬀect on Xylazine/Ketamine-Induced Anesthesia. The
durations of xylazine/ketamine-induced anesthesia in con-
trol (vehicle) mice of the biochanin A- and Ro 20-1724-
treated groups were 25.0 ± 2.7( n = 13) and 21.8 ± 1.7min
(n = 21), respectively. Biochanin A (30∼300μmol/kg, s.c.)
did not signiﬁcantly aﬀect the duration (Figure 5(a)). How-
ever, Ro 20-1724 (0.01∼1μmol/kg, s.c.) dose-dependently
shortened the duration, and at doses of 0.1 and 1μmol/kg
(s.c.) signiﬁcantly shortened the duration (Figure 5(b)).
3.7. Inhibition of OVA-Induced Contractions In Vitro. For
sensitized guinea pig trachea in isolation, 60mM of KCl
evoked contractions and increased tension to 968 ± 35mg
(n = 54) that was set to 100%. OVA (0.01∼100μg/mL)
concentration-dependently enhanced the tension from the
baseline to 110.4% ± 5.2% (n = 8) of the 60mM KCl-
induced contractions (Figure 6(a)). The log concentration-
response curve of OVA was unaltered by 1μM nifedipine
(data not shown), a selective voltage-dependent calcium6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of biochanin A (30∼100μmol/kg, p.o.) on Penh (a), inﬂammatory cells (b), and cytokines (c) in sensitized mice receiving
aerosolized methacholine (MCh, 6.25∼50mg/mL) 2 days after primary allergen challenge. #P<. 05, ##P<. 01, and ###P<. 001, compared
to the nonchallenged group. ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001, compared to the control (vehicle) group. The number of mice in each
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channel blocker [26], although it signiﬁcantly relaxed 194 ±
67mg (n = 3) from the baseline tension after a 15-min
preincubation at this concentration. Biochanin A (10 and
30μM) concentration-dependently and signiﬁcantly relaxed
respective 217±44mg (n = 6) and 416±76mg (n = 6) from
the baseline tension, and inhibited OVA (10∼100μg/mL)-
inducedcontractions (Figure 6(a)). Similarly, Ro20-1724 (3,
10, and 30μM) concentration-dependently and signiﬁcantly
relaxed respective 297 ± 83mg (n = 5), 434 ± 109mg (n =
5) and 731 ± 91mg (n = 5 )f r o mt h eb a s e l i n et e n s i o n ,
and inhibited OVA (10∼100μg/mL)-induced contractions
(Figure 6(b)). The IC50 value of biochanin A for inhibiting
OVA (100μg/mL)-induced contractions was calculated as
8.1 ±0.8μM( n = 5).
4.Discussion
Allergic asthma is a chronic respiratory disease characterized
by AHR, mucus hypersecretion, bronchial inﬂammation,
and elevated IgE levels. T-helper type 2 (Th2) cells, together
with other inﬂammatory cells such as eosinophils, B cells,
and mast cells were proposed as critical to the initiation,
development, and chronicity of this disease [27]. One
hypothesis emphasized an imbalance in Th cell populations
favoring the expression of Th2 over Th1 cells. Cytokines
released from Th2 cells are IL-4, IL-5, IL-6, IL-9, and IL-13,
and those from Th1 cells are IL-2, IL-12, IFN-γ,a n dT N F - α
[28,29].Althoughthesolubilityandabsorptionofbiochanin
A,anisoﬂavone,ispoor,biochaninA(100μmol/kg,p.o.)wasEvidence-Based Complementary and Alternative Medicine 7
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observed to signiﬁcantly decrease RL (Figure 2(a)), increase
Cdyn (Figure 2(b)) and reduce Penh values (Figure 3(a))
suggesting that it signiﬁcantly suppresses AHR. It also
suppressed the number of total inﬂammatory cells, neu-
trophils, and eosinophils in the BALF of sensitized and
challenged mice (Figure 3(b)). The reason that macrophages
and lymphocytes were not inﬂuenced by biochanin A at
this dose is unclear. Biochanin A (100μmol/kg, p.o.) also
suppressed levels of IL-2, IL-4, IL-5, and TNF-α. Biochanin
Ae v e na t3 0 μmol/kg (p.o.) signiﬁcantly suppressed levels
of IL-4, and IL-5, although it did not inﬂuence all types of
inﬂammatory cells at this dose. However, the level of IFN-
γ was unaﬀected by 30 or 100μmol/kg (p.o.) biochanin A.
These results suggest that biochanin A suppresses both Th2
andTh1cellsthatwereimplicatedinautoimmuneandatopic
diseases, respectively [30]. On the other hand, biochanin A
was reported to enhance IL-4 production in activated T cells
through two independent pathways [31]. This in vitro result8 Evidence-Based Complementary and Alternative Medicine
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is inconsistent with our present in vivo results, but thereason
is unclear.
IL-4 and IL-13 were shown to induce AHR in mouse
asthma models [32, 33]. IL-4 has three primary eﬀects. First,
IL-4 promotes B cell diﬀerentiation to plasma cells secreting
antigen-speciﬁc IgE antibodies. Second, IL-4 promotes mast
cell proliferation. Third, increased IL-4 upregulatesendothe-
lial cell expression of adhesion molecules for eosinophils
[34]. IL-5 mobilizes and activates eosinophils, leading to
a release of major basic proteins, cysteinyl-leukotrienes,
and eosinophil peroxidase that contribute to tissue damage
and AHR [33, 35]. Phosphoinositide 3-kinase δ (p110δ)
was shown to play a crucial role in the development,
diﬀerentiation, and antigen receptor-induced proliferation
of mature B cells [36, 37]. Inhibition of p110δ attenuates
allergic inﬂammation in airways and AHR in a murine
asthma model [37, 38]. In addition, IL-4 and IL-13 are
important in directing B cell growth, diﬀerentiation, andEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: Mechanisms involved in the action of Biochanin A. Biochanin A selectively inhibits phosphodiesterase (PDE)4 activity resulting
in an increase in cAMP, activating cAMP dependent protein kinase (PKA) and increasing calcium extrusion from the intracellular space
and uptake to sarcoplasmic reticula (SR). Biochanin A largely decreased the concentration of intracellular calcium ([Ca2+]i)r e s u l t i n gi n
trachobronchial smoothmusclerelaxation. The increase in cAMP alsohad anti-inﬂammatoryand immunoregulatory eﬀects. AC, adenylate
cyclase; Th, T-helper cells; Ig, immunoglobulin;IL, interleukin; TNF-α, tumornecrosis factor-α. Up anddown arrows indicate increases and
decreases, respectively.
the secretion of IgE [39]. However, IFN-γ released from
Th1 cells preferentially directs B cell switching of IgM to
IgG2a and IgG3 in mice [40, 41]. The biological activities
of IgE are mediated through the high-aﬃnity IgE receptor
(FcεRI) on mast cells and basophils. Cross-linking of the
FcεRI initiates multiple signal cascades leading to cellular
degranulation and activation [42, 43]. The activity of p110δ
was reported to be critical for allergen-IgE-induced mast cell
degranulation and the release of cytokines [44]. Inhibition
of p110δ therefore attenuates the production of IgE as well
as allergen-IgE-induced mast cell activation during allergic
inﬂammation. Itwassuggestedthatcalciumchannelsinmast
cell membranes diﬀer from those in cardiovascular tissues
[45], which are sensitive to nifedipine. In the present in vitro
results, nifedipine (1μM) signiﬁcantly relaxed the baseline
tension but did not inﬂuence the cumulative OVA-induced
contractions of isolated sensitized guinea pig trachealis,
suggesting that nifedipine did not inhibit degranulation of
mast cells [46], because nifedipine has no anti-inﬂammatory
eﬀects. In contrast, biochanin A (10∼30μM) signiﬁcantly
relaxed the baseline tension and inhibited cumulative OVA-
induced contractions in isolated sensitized guinea pig tra-
chealis,suggestingthatbiochaninAinhibitsdegranulationof
mast cells and, at least partially, prevents inﬂammation. This
inhibition is unrelated to its relaxant eﬀects on smooth mus-
cle. Although biochanin A possesses both smooth muscle
relaxantandanti-inﬂammatory eﬀects,itinhibitscumulative
OVA-induced contractions in isolated sensitized guinea pig
trachealis due mainly to its anti-inﬂammatory eﬀects. The
IC50 value of biochanin A for inhibiting OVA (100μg/mL)-
induced contractions was calculated to be 8.1μM, and is
similar to that (8.5μM) for inhibiting PDE4 activity [6]. In
addition, biochanin A (100μmol/kg, p.o.) dose-dependently
and signiﬁcantly suppressedtotalandOVA-speciﬁcIgElevels
in the serum and BALF, and enhanced the level of total IgG2a
in the serum of sensitized and challenged mice, suggesting
that biochanin A has immunoregulatory eﬀects.
Selective PDE4 inhibitors speciﬁcally prevent the hydrol-
ysis of cAMP, a 3
 ,5
 -cyclic nucleotide, and therefore have
broad anti-inﬂammatory eﬀects such as the inhibition of
cell traﬃcking and of cytokine and chemokine release from
inﬂammatory cells. The second-generation PDE4 inhibitors,
cilomilast and roﬂumilast have reached the clinical trial stage
and exhibited a number of beneﬁcial eﬀects for treating
asthma and COPD [47]. The eﬀectiveness of these PDE4
inhibitors may be limited by their clinical potency when
using doses that have minimal adverse eﬀects on headaches,
diarrhea, nausea, and abdominal pain. The PDE4H/PDE4L
ratios of cilomilast and roﬂumilast were reported to be
117.8nM/120nM (1), and 2.4nM/0.8nM (3), respectively
[15, 48], and are considerably greater than those (0.01∼
0.001) of rolipram [16]. Due to its adverse eﬀects or lack
of eﬃcacy, cilomilast was discontinued for asthma treatment
after phase II clinical trials in 2003 [47]. In terms of
tolerability over 6 months with 15 mg twice daily for COPD
in a phase III study, cilomilast was found to be associated
with higher frequencies of diarrhea and nausea than with a
placebo [47]. Roﬂumilast is still being evaluated for asthma
and COPD in phase III clinical trials at present, and is
reported to reduce those adverse eﬀects after longer-term
treatment at 0.5mg once daily [47]. Recently, roﬂumilast
was reported to signiﬁcantly improve mean pre- or post-
bronchodilator forced expiratory volume for 1s (FEV1)
in patients with moderate-to-severe COPD, compared to
a placebo. However, nausea, diarrhea, weight loss, and
headache were more frequent in patients in the roﬂumilast10 Evidence-Based Complementary and Alternative Medicine
group. These adverse events were associated with an increase
in patient withdrawal [49, 50]. The PDE4H/PDE4L ratio of
AWD 12-281, another selective PDE4 inhibitor, was reported
to be 104nM/9.7nM (approximately 11) [13]. AWD 12-281
has been undergoing clinical developmentphase IIa trials for
COPD, and has been reported as a potentially unique drug
for the topical treatment of asthma and COPD [51]. AWD
12-281 was reported as a very promising drug for treating
lung inﬂammation when administered by inhalation and for
treating atopic dermatitis [52]. However, AWD-12-281 was
also discontinued in clinical trials of both asthma and COPD
owing to its lack of eﬃcacy[53, 54]. Many compounds are in
developmentbuthaveyettoreach themarketasamonother-
apy, and will remain so until the emetic liability has been
reduced. However, inhaled GSK256066 has demonstrated
eﬃcacy in trials for asthma [55] and an oral apremilast
was reported to be clinically eﬀective for treating severe
plaque-type psoriasis [56]. Another strategy for developing
new PDE4 inhibitors may consider PDE4 subtypes (A∼D).
PDE4D inhibition in nontarget tissues promotes emesis,
because the PDE4D knock-out mice showed a reduction
in anesthesia triggered by xylazine/ketamine, which is used
as a surrogate marker for emesis in mice, a nonvomiting
species [22]. Recently, small-molecule allosteric modulators
of PDE4D that do not completely inhibit enzymatic activity
were reported to reduce emesis and to have therapeutic
beneﬁt for brain distribution, such as Alzheimer’s disease,
Huntington’s disease, schizophrenia, and depression [57].
In contrast, selective inhibition of PDE4A and/or PDE4B
in pro-inﬂammatory and immune cells is believed to evoke
the therapeutically desired eﬀects of these drugs [58].
Compared to PDE4A and PDE4B, cilomilast has a higher
potency for PDE4D, while roﬂumilast is nonselective for
these four PDE4 subtypes with a similar degree of inhibition
[59]. No research into the role of AWD 12-281 in the
inhibition of PDE4 subtypes has been conducted. Whether
Biochanin A selectively inhibits PDE4 subtype requires
further investigation. The increased cAMP levels induced
by these selective PDE4 inhibitors activate cAMP-dependent
protein kinase which may phosphorylate and inhibit myosin
light-chain kinase, thus inhibiting contractions [60]. The
precise mechanism by which relaxation is produced by this
second-messenger pathway is unknown, but it may result
from a decrease in intracellular Ca2+ ([Ca2+]i). The decrease
in [Ca2+]i may be due to a reduction in the inﬂux of
Ca2+,e n h a n c e dC a 2+ uptake into the sarcoplasmic reticula,
or enhanced Ca2+ extrusion through the cell membrane
[60]. Biochanin A was reported to relax isolated rabbit
b a s i l a ra r t e r i e sb yam e c h a n i s mo fC a 2+ entry blockade [61].
Because biochanin A is a selective PDE4 inhibitor [6], this
compound should have the eﬀectof decreasing [Ca2+]i and a
relaxant eﬀect in isolated guinea pig trachea. Consequently,
red clover has been reported to have an antispasmodic
eﬀect in previous literature [3]. In contrast to animals, a
single dose of cilomilast [62]o rr o ﬂ u m i l a s t[ 63]p e rd a y
w a sr e p o r t e dt oh a v en ob r o n c h o d i l a t o re ﬀect on humans.
Whether biochanin A has bronchodilator eﬀect requires
investigation in randomized, placebo-controlled clinical
studies.
Following oral administration of biochanin A, genistein,
a demethylated metabolite of biochanin A, may have been
produced. Biochanin A and genistein have been reported to
inhibit protein tyrosine kinase (PTK) of epidermal growth
factor receptor with IC50 values of 91.5μMa n d2 . 6 μM,
respectively [64] .I nag u i n e ap i gm o d e lo fa s t h m a ,g e n i s t e i n
was reported to have anti-inﬂammatory eﬀects in airway
via PTK inhibition [65]. Moreover, an increase in the
consumption of soy genistein was reported to be associated
with improved lung function in patients with asthma [66].
In clinical trials, compared to subjects receiving a placebo,
subjects receiving genistein (54mg/day for 2 years) revealed
a signiﬁcantly (19% versus 8%, P = .002) higher incidence
of discontinued therapy following adverse gastrointestinal
events, such as abdominal pain, epigastric pain, dyspepsia,
and constipation [67]. In a murine model of allergic asthma,
we also reported that genistein concentration-dependently
inhibited 2nM [3H]-rolipram bound to HARBSs of brain
cell membranes and shortened xylazine/ketamine-induced
anesthesia at a dose level of 100μmol/kg (s.c.), suggest-
ing that higher doses of genistein may induce adverse
gastrointestinal side eﬀects [68]. However, in the present
results, biochanin A, even at 300μmol/kg (s.c.), did not
shorten this kind of anesthesia. This suggests that biochanin
A, 1h after injection (s.c.), is demethylated slightly to
form genistein. In the present in vivo study, biochanin A
(100μmol/kg, p.o.) signiﬁcantly enhanced the total serum
IgG2a levels, which had probably switched from IgM due
to an increase in IFN-γ level [40, 41]. The increased IFN-γ
levels may have been oﬀset by genistein, which has recently
been reported to inhibit IFN-γ levels [68], when biochanin
A is demethylated. These results suggest that 24∼50 h
after oral administration, biochanin A is demethylated to
produce genistein. Thus, long-term use of biochanin A may
cause adverse gastrointestinal eﬀects, such as abdominal
pain, epigastric pain, dyspepsia, and constipation, partic-
ularly at higher doses. However, accurately determining
the concentration of biochanin A and the demethylated
metabolites in the blood requires further pharmacokinetic
investigation.
In the present results, the PDE4H value of biochanin
Aw a s>300μM, suggesting that it had a low aﬃnity for
HARBSs of brain cell membranes. Thus the PDE4H/PDE4L
ratio ofbiochanin Awas >35,which wasconsiderablygreater
than that of AWD 12-281. In addition, biochanin A did
not inﬂuence xylazine/ketamine-induced anesthesia. These
results are consistent with the low aﬃnity of biochanin
A for HARBSs of brain cell membranes. However, Ro
20-1724, a selective PDE4 inhibitor, reversed the anes-
thetic eﬀects. This reversal may have occurred through
presynaptic α2-adrenoceptor inhibition [69], because MK-
912, an α2-adrenoceptor antagonist, has been reported to
reverse xylazine/ketamine-induced anesthesia in rats [70]
and trigger vomiting in ferrets [69]. In contrast, clonidine,
an α2-adrenoceptor agonist, prevented emesis induced by
PDE4 inhibitors in ferrets [69]. In the present results,
the fact that biochanin A did not reverse the duration of
xylazine/ketamine-induced anesthesia may have been due to
a lack of genistein demethylated from biochanin A.Evidence-Based Complementary and Alternative Medicine 11
In conclusion, the present results support the traditional
use of red clovercontaining biochanin A for the treatment of
allergic asthma and COPD, despite evidence of adverse gas-
trointestinaleﬀectsfollowinglongtimeuse.Themechanisms
of biochanin A are summarized in Figure 7.
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